North Point Portfolio Managers Corp OH Sells 128 Shares of Chemed Co. (NYSE:CHE)

North Point Portfolio Managers Corp OH trimmed its stake in Chemed Co. (NYSE:CHEFree Report) by 0.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,902 shares of the company’s stock after selling 128 shares during the period. North Point Portfolio Managers Corp OH owned about 0.11% of Chemed worth $9,883,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the stock. Larson Financial Group LLC purchased a new stake in shares of Chemed in the third quarter valued at approximately $44,000. Canada Pension Plan Investment Board bought a new position in shares of Chemed during the 1st quarter worth $46,000. Legacy Financial Group LLC purchased a new position in shares of Chemed during the third quarter valued at $48,000. Fortis Capital Advisors LLC raised its holdings in shares of Chemed by 155.6% in the first quarter. Fortis Capital Advisors LLC now owns 115 shares of the company’s stock valued at $62,000 after acquiring an additional 70 shares in the last quarter. Finally, CENTRAL TRUST Co lifted its stake in Chemed by 2,283.3% in the third quarter. CENTRAL TRUST Co now owns 143 shares of the company’s stock worth $62,000 after acquiring an additional 137 shares during the period. 95.85% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on CHE. Royal Bank of Canada increased their price objective on shares of Chemed from $604.00 to $712.00 and gave the company an “outperform” rating in a research note on Monday, March 4th. Oppenheimer increased their target price on Chemed from $625.00 to $650.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th.

View Our Latest Research Report on Chemed

Insider Activity at Chemed

In other Chemed news, VP Brian C. Judkins sold 11,158 shares of Chemed stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $645.00, for a total transaction of $7,196,910.00. Following the completion of the sale, the vice president now owns 1,422 shares of the company’s stock, valued at approximately $917,190. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, VP Brian C. Judkins sold 11,158 shares of the stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $645.00, for a total value of $7,196,910.00. Following the sale, the vice president now owns 1,422 shares in the company, valued at $917,190. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Michael D. Witzeman sold 2,650 shares of the business’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $643.14, for a total transaction of $1,704,321.00. Following the transaction, the chief financial officer now owns 2,882 shares of the company’s stock, valued at $1,853,529.48. The disclosure for this sale can be found here. Insiders have sold a total of 15,808 shares of company stock valued at $10,184,531 in the last ninety days. Company insiders own 3.80% of the company’s stock.

Chemed Price Performance

Chemed stock traded down $2.35 during midday trading on Wednesday, reaching $634.47. The company’s stock had a trading volume of 6,407 shares, compared to its average volume of 79,878. The stock has a market capitalization of $9.59 billion, a P/E ratio of 35.50, a PEG ratio of 2.57 and a beta of 0.42. The stock’s 50-day simple moving average is $616.07 and its 200-day simple moving average is $579.61. Chemed Co. has a 52-week low of $492.84 and a 52-week high of $654.62.

Chemed (NYSE:CHEGet Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The company reported $6.60 EPS for the quarter, beating the consensus estimate of $6.25 by $0.35. The firm had revenue of $585.90 million during the quarter, compared to analyst estimates of $586.64 million. Chemed had a net margin of 12.03% and a return on equity of 32.29%. Chemed’s revenue was up 7.2% on a year-over-year basis. During the same period last year, the firm posted $5.39 EPS. As a group, equities research analysts expect that Chemed Co. will post 21.99 earnings per share for the current fiscal year.

Chemed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Monday, February 26th were issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.25%. The ex-dividend date was Friday, February 23rd. Chemed’s dividend payout ratio (DPR) is presently 8.93%.

About Chemed

(Free Report)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Featured Stories

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHEFree Report).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.